[1] Perumpail B, Khan M, Yoo E, et al. Clinical epidemiology and disease burden of nonalcoholic fatty liver disease. World J Gastroenterol, 2017; 23, 8263. doi:  10.3748/wjg.v23.i47.8263
[2] Dongiovanni P, Valenti L. Genetics of nonalcoholic fatty liver disease. Metabolism, 2016; 65, 1026. doi:  10.1016/j.metabol.2015.08.018
[3] Varki A, Cummings RD, Esko JD, et al. Biological Roles of Glycans-Essentials of Glycobiology. Cold Spring Harbor Laboratory Press, 2009; 6, 65-72. http://www.ncbi.nlm.nih.gov/pubmed/20301233
[4] Mehta AS, Long RE, Comunale MA, et al. Increased levels of galactose-deficient anti-Gal immunoglobulin G in the sera of hepatitis C virus-infected individuals with fibrosis and cirrhosis. J Virol, 2008; 82, 1259-70. doi:  10.1128/JVI.01600-07
[5] Wang Y, Klaric L, Yu X, et al. The Association Between Glycosylation of Immunoglobulin G and Hypertension:A Multiple Ethnic Cross-Sectional Study. Medicine, 2016; 95, e3379. doi:  10.1097/MD.0000000000003379
[6] Farrell GC, Chitturi S, Lau GK, et al. Guidelines for the assessment and management of non-alcoholic fatty liver disease in the Asia-Pacific region:executive summary. J Gastroenterol Hepatol, 2007; 22, 775-7. doi:  10.1111/jgh.2007.22.issue-6
[7] Fan JG, Jia JD, Li YM, et al. Guidelines for the diagnosis and management of nonalcoholic fatty liver disease:Update 2010. J Dig Dis, 2011; 12, 38-44. doi:  10.1111/j.1751-2980.2010.00476.x
[8] Chen C, Schmilovitz-weiss H, Liu XE, et al. Serum protein N-glycans profiling for the discovery of potential biomarkers for nonalcoholic steatohepatitis. J Proteome Res, 2009; 8, 463-70. doi:  10.1021/pr800656e
[9] Clarke JD, Novak P, Lake AD, et al. Impaired N-linked glycosylation of uptake and efflux transporters in human non-alcoholic fatty liver disease. Liver Int, 2017; 37, 1074. doi:  10.1111/liv.2017.37.issue-7
[10] Lauc G, Pezer M, Rudan I, et al. Mechanisms of disease:The human N-glycome. Biochim Biophys Acta, 2016; 1860, 1574-82. doi:  10.1016/j.bbagen.2015.10.016
[11] Selman MH, Niks EH, Titulaer MJ, et al. IgG fc N-glycosylation changes in Lambert-Eaton myasthenic syndrome and myasthenia gravis. J Proteome Res, 2011; 10, 143-52. doi:  10.1021/pr1004373
[12] Wuhrer M, Selman MHJ, Mcdonnell LA, et al. Pro-inflammatory pattern of IgG1 Fc glycosylation in multiple sclerosis cerebrospinal fluid. J Neuroinflammation, 2015; 12, 235. doi:  10.1186/s12974-015-0450-1
[13] Gasdaska JR, Sherwood S, REGAN JT, et al. An afucosylated anti-CD20 monoclonal antibody with greater antibody-dependent cellular cytotoxicity and B-cell depletion and lower complement-dependent cytotoxicity than rituximab. Mol Immunol, 2012; 50, 134-41. doi:  10.1016/j.molimm.2012.01.001